Literature DB >> 3485487

Procainamide elicits a selective autoantibody immune response.

R L Rubin, G Reimer, E M McNally, S R Nusinow, R P Searles, E M Tan.   

Abstract

The specificity of the in vivo humoral immune response elicited by procainamide was examined by solid-phase assays, immunofluorescence, immunoprecipitation and a cytotoxicity assay. Serial samples obtained from patients during their procainamide therapy showed a progressive increase in antibodies to histones and denatured DNA, and both activities decreased after discontinuation of therapy. In contrast antibodies to tetanus, human IgG (rheumatoid factor) and heterologous lymphocytes were unaffected by procainamide treatment, indicating that they were not drug-induced. Of 29 sera examined by protein-A-facilitated immunoprecipitation, four sera had antibody to ribosomal RNA and three sera immunoprecipitated a 40kD protein. Antinuclear antibodies were invariably present but absorption studies showed that these activities were due to anti-histone antibodies. These results indicate that procainamide-induced autoimmunity is characterized predominantly by an anti-histone and anti-denatured DNA immune response.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485487      PMCID: PMC1577356     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

1.  Two novel classes of small ribonucleoproteins detected by antibodies associated with lupus erythematosus.

Authors:  M R Lerner; J A Boyle; J A Hardin; J A Steitz
Journal:  Science       Date:  1981-01-23       Impact factor: 47.728

2.  Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome.

Authors:  R L Woosley; D E Drayer; M M Reidenberg; A S Nies; K Carr; J A Oates
Journal:  N Engl J Med       Date:  1978-05-25       Impact factor: 91.245

3.  Immune regulatory abnormalities produced by procainamide.

Authors:  K B Miller; D Salem
Journal:  Am J Med       Date:  1982-10       Impact factor: 4.965

4.  Molecular characterization of ribonucleoprotein antigens bound by antinuclear antibodies. A diagnostic evaluation.

Authors:  L Matter; K Schopfer; J A Wilhelm; T Nyffenegger; R F Parisot; E M De Robertis
Journal:  Arthritis Rheum       Date:  1982-11

5.  Immunological responses of healthy elderly population.

Authors:  J S Goodwin; R P Searles; K S Tung
Journal:  Clin Exp Immunol       Date:  1982-05       Impact factor: 4.330

6.  Lymphocyte alteration by procainamide: relation to drug-induced lupus erythematosus syndrome.

Authors:  H G Bluestein; N J Zvaifler; M H Weisman; R F Shapiro
Journal:  Lancet       Date:  1979-10-20       Impact factor: 79.321

7.  Development of antibodies to ribonucleoprotein following short-term therapy with procainamide.

Authors:  J B Winfield; D Koffler; H G Kunkel
Journal:  Arthritis Rheum       Date:  1975 Nov-Dec

8.  Histone reactivity of drug-induced antinuclear antibodies. A comparison of symptomatic and asymptomatic patients.

Authors:  L Grossman; P Barland
Journal:  Arthritis Rheum       Date:  1981-07

9.  Interaction between VA RNA and the lupus antigen La: formation of a ribonucleoprotein particle in vitro.

Authors:  A M Francoeur; M B Mathews
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

10.  Immunomodulatory effect of procainamide in man. Inhibition of human suppressor T-cell activity in vitro.

Authors:  T Ochi; E A Goldings; P E Lipsky; M Ziff
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

View more
  9 in total

Review 1.  Idiosyncratic drug reactions: possible role of reactive metabolites generated by leukocytes.

Authors:  J P Uetrecht
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

2.  Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin.

Authors:  R W Burlingame; R L Rubin
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

3.  The effects of selected drugs, including chlorpromazine and non-steroidal anti-inflammatory agents, on polyclonal IgG synthesis and interleukin 1 production by human peripheral blood mononuclear cells in vitro.

Authors:  F Martinez; J W Coleman
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

4.  Kinetics and pathogenicity of autoantibodies induced by mercuric chloride in the brown Norway rat.

Authors:  C D Pusey; C Bowman; A Morgan; A P Weetman; B Hartley; C M Lockwood
Journal:  Clin Exp Immunol       Date:  1990-07       Impact factor: 4.330

5.  Elevated autoimmunity in residents living near abandoned uranium mine sites on the Navajo Nation.

Authors:  Esther Erdei; Chris Shuey; Bernadette Pacheco; Miranda Cajero; Johnnye Lewis; Robert L Rubin
Journal:  J Autoimmun       Date:  2019-03-14       Impact factor: 7.094

6.  Increased presence of common systemic lupus erythematosus (SLE) anti-DNA idiotypes (16/6 Id, 32/15 Id) is induced by procainamide.

Authors:  Y Shoenfeld; Y Vilner; T Reshef; A Klajman; A Skibin; O Kooperman; R C Kennedy
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

7.  Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex.

Authors:  R L Rubin; S A Bell; R W Burlingame
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

8.  Autoantibodies to nucleolin cross-react with histone H1 in systemic lupus erythematosus.

Authors:  W N Jarjour; S Minota; R A Roubey; T Mimura; J B Winfield
Journal:  Mol Biol Rep       Date:  1992-09       Impact factor: 2.316

9.  Systemic lupus erythematosus induced by isoniazid.

Authors:  M Salazar-Páramo; R L Rubin; I García-De La Torre
Journal:  Ann Rheum Dis       Date:  1992-09       Impact factor: 19.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.